Targeting sphingosine kinase 1 (SphK1) and apoptosis by colon-specific delivery formula of resveratrol in treatment of experimental ulcerative colitis in rats

European Journal of Pharmacology

Volumn 718, Issue 1-3, 2013, Pages 145-153

  Abdin, Amany A ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Colon specific delivery formula; Sesveratrol; Sphingosine kinase; Ulcerative colitis

Indexed keywords

CALCIUM PECTINATE; CASPASE 3; DRUG CARRIER; MYELOPEROXIDASE; PECTIN; RESVERATROL; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX; DISEASE CONTROL; DISEASE COURSE; DNA FRAGMENTATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SCORING SYSTEM; ULCERATIVE COLITIS;

COLON-SPECIFIC DELIVERY FORMULA; SESVERATROL; SPHINGOSINE KINASE; ULCERATIVE COLITIS;

ANIMALS; APOPTOSIS; CASPASE 3; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; COLON; DNA FRAGMENTATION; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR TARGETED THERAPY; ORGAN SPECIFICITY; OXAZOLONE; PEROXIDASE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RATS; RATS, WISTAR; STILBENES;

EID: 84887074576     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.08.040     Document Type: Article

References (85)

1. D.M. Abdallah, and N.R. Ismael Resveratrol abrogates adhesion molecules and protects against TNBS-induced ulcerative colitis in rats Canadian Journal of Physiology and Pharmacology 89 2011 811 818
2. S.M. Aljanabi, and I. Martinez Universal and rapid salt-extraction of high quality genomic DNA for PCR-based techniques Nucleic Acids Research 25 1997 4692 4693 (Pubitemid 27500787)
3. L. Almeida, M. Vaz-da-Silva, A. Falcão, E. Soares, R. Costa, A.I. Loureiro, C. Fernandes-Lopes, J.F. Rocha, T. Nunes, L. Wright, and P. Soares-da-Silva Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers Molecular Nutrition and Food Research 53 Suppl. 1 2009 S7 S15
4. A. Amri, J.C. Chaumeil, S. Sfar, and C. Charrueau Administration of resveratrol: what formulation solutions to bioavailability limitations? Journal of Controlled Release 158 2012 182 193
5. Y. Araki, K. Mukaisyo, H. Sugihara, Y. Fujiyama, and T. Hattori Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice Oncology Reports 24 2010 869 874
6. J.D. Bancroft, A. Steven, and D.R. Turner 1996 New york, Edinburgh, London, Madried, Churchill Livingston Melbourne, San Francisco, Tokyo (pp.121-129, 140)
7. M. Boirivant, I.J. Fuss, A. Chu, and W. Strober Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4 Journal of Experimental Medicine 188 1998 1929 1939 (Pubitemid 28536780)
8. D.J. Boocock, G.E. Faust, K.R. Patel, A.M. Schinas, V.A. Brown, M.P. Ducharme, T.D. Booth, J.A. Crowell, M. Perloff, A.J. Gescher, W.P. Steward, and D.E. Brenner Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent Cancer Epidemiology, Biomarkers and Prevention 16 2007 1246 1252 (Pubitemid 46984966)
9. P.P. Bradley, D.A. Priebat, R.D. Christensen, and G. Rothstein Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker Journal of Investigative Dermatology 78 1982 206 209 (Pubitemid 12171880)
10. F. Brisdelli, G. D'Andrea, and A. Bozzi Resveratrol: a natural polyphenol with multiple chemopreventive properties Current Drug Metabolism 10 2009 530 546
11. M.K. Chourasia, and S.K. Jain Pharmaceutical approaches to colon targeted drug delivery systems Journal of. Pharmacy and Pharmaceutical. Sciences 6 2003 33 66 (Pubitemid 37207241)
12. H.S. Cooper, S.N. Murthy, R.S. Shah, and D.J. Sedergran Clinicopathologic study of dextran sulfate sodium experimental murine colitis Laboratory Investigation 69 1993 238 249
13. J.A. Crowell, P.J. Korytko, R.L. Morrissey, T.D. Booth, and B.S. Levine Resveratrol-associated renal toxicity Toxicological Sciences 82 2004 614 619 (Pubitemid 39600090)
14. X. Cui, Y. Jin, A.B. Hofseth, E. Pena, J. Habiger, A. Chumanevich, D. Poudyal, M. Nagarkatti, P.S. Nagarkatti, U.P. Singh, and L.J. Hofseth Resveratrol suppresses colitis and colon cancer associated with colitis Cancer Prevention Research (Philadelphia) 3 2010 549 559
15. S. Danese, and C. Fiocchi Ulcerative colitis New England Journal of Medicine 365 2011 1713 1725
16. S. Danese, M. Sans, and C. Fiocchi Inflammatory bowel disease: the role of environmental factors Autoimmunity Reviews 3 2004 394 400 (Pubitemid 38993362)
17. S. Das, A. Chaudhury, and K.Y. Ng Preparation and evaluation of zinc-pectin-chitosan composite particles for drug delivery to the colon: role of chitosan in modifying in vitro and in vivo drug release International Journal of Pharmaceutics 406 2011 11 20
18. S. Das, and K.Y. Ng Colon-specific delivery of resveratrol: optimization of multi-particulate calcium-pectinate carrier International Journal of Pharmaceutics 385 2010 20 28
19. C.A. de la Lastra, and I. Villegas Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications Biochemical Society Transactions 35 2007 1156 1160 (Pubitemid 350206449)
20. Y. Edmonds, S. Milstien, and S. Spiegel Development of small-molecule inhibitors of sphingosine-1-phosphate signaling Pharmacology and Therapeutics 132 2011 352 360
21. K.J. French, R.S. Schrecengost, B.D. Lee, Y. Zhuang, S.N. Smith, J.L. Eberly, J.K. Yun, and C.D. Smith Discovery and evaluation of inhibitors of human sphingosine kinase Cancer Research 63 2003 5962 5969 (Pubitemid 37187498)
22. D.R. Friend New oral delivery systems for treatment of inflammatory bowel disease Advanced Drug Delivery Reviews 57 2005 247 265 (Pubitemid 39536101)
23. Y. Fukuda, A. Kihara, and Y. Igarashi Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1 Biochemical and Biophysical Research Communications 309 2003 155 160 (Pubitemid 36999771)
24. D.R. Gude, S.E. Alvarez, S.W. Paugh, P. Mitra, J. Yu, R. Griffiths, S.E. Barbour, S. Milstien, and S. Spiegel Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal FASEB Journal 22 2008 2629 2638
25. V. Gurtu, S.R. Kain, and G. Zhang Fluorometric and colorimetric detection of caspase activity associated with apoptosis Analytical Biochemistry 251 1997 98 102 (Pubitemid 27352149)
26. N.C. Hait, C.A. Oskeritzian, S.W. Paugh, S. Milstien, and S. Spiegel Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases Biochimica Biophysica Acta 1758 2006 2016 2026 (Pubitemid 44879368)
27. S.E. Hassab El-Nabi Molecular and cytogenic studies on the antimutagenic potential of eugenol in human lymphocytes culture treated with depakine and apetryl drugs Journal of Egyptian German Society of Zoology 43c 2004 171 196
28. K.A. Head, and J.S. Jurenka Inflammatory bowel disease Part 1: ulcerative colitis - pathophysiology and conventional and alternative treatment options Alternative Medicine Review 8 2003 247 283 (Pubitemid 37099887)
29. V. Hebbar, G. Shen, R. Hu, B.R. Kim, C. Chen, P.J. Korytko, J.A. Crowell, B.S. Levine, and A.N. Kong Toxicogenomics of resveratrol in rat liver Life Sciences 76 2005 2299 2314 (Pubitemid 40313418)
30. F. Heller, I.J. Fuss, E.E. Nieuwenhuis, R.S. Blumberg, and W. Strober Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells Immunity 17 2002 629 638 (Pubitemid 35351508)
31. K. Itagaki, and C.J. Hauser Sphingosine 1-phosphate, a diffusible calcium influx factor mediating store-operated calcium entry Journal of Biological Chemistry 278 2003 27540 27547 (Pubitemid 36899938)
32. P.D. Issuree, P.N. Pushparaj, S. Pervaiz, and A.J. Melendez Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities FASEB Journal 23 2009 2412 2424
33. M.E. Juan, M.P. Vinardell, and J.M. Planas The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful Journal of Nutrition 132 2002 257 260 (Pubitemid 34135604)
34. M. Karin The IkappaB kinase - a bridge between inflammation and cancer Cell Research 18 2008 334 342 (Pubitemid 351333897)
35. T. Kawamori, T. Kaneshiro, M. Okumura, S. Maalouf, A. Uflacker, J. Bielawski, Y.A. Hannun, and L.M. Obeid Role for sphingosine kinase 1 in colon carcinogenesis FASEB Journal 23 2009 405 414
36. S. Kitajima, S. Takuma, and M. Morimoto Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium Experimental Animals 48 1999 137 143 (Pubitemid 129558679)
37. R. Kojima, S. Kuroda, T. Ohkishi, K. Nakamaru, and S. Hatakeyama Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis Journal of Pharmacological Science 96 2004 307 313 (Pubitemid 40013340)
38. A. Kornbluth, and D.B. Sachar Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee American Journal of Gastroenterology 99 2004 1371 1385 (Pubitemid 39062279)
39. T.E. Kraft, D. Parisotto, C. Schempp, and T. Efferth Fighting cancer with red wine? Molecular mechanisms of resveratrol Critical Reviews in Food Science and Nutrition 49 2009 782 799
40. G. Kroemer, and S.J. Martin Caspase-independent cell death Nature Medicine 11 2005 725 730 (Pubitemid 41021204)
41. J. Kunisawa, and H. Kiyono Immunological function of sphingosine 1-phosphate in the intestine Nutrients 4 2012 154 166
42. C. la Porte, N. Voduc, G. Zhang, I. Seguin, D. Tardiff, N. Singhal, and D.W. Cameron Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects Clinical Pharmacokinetics 49 2010 449 454
43. T.M. Leclercq, and S.M. Pitson Cellular signalling by sphingosine kinase and sphingosine 1-phosphate IUBMB Life. 58 2006 467 472 (Pubitemid 44266907)
44. Z.F. Li, X.M. Xia, C. Huang, S. Zhang, J. Zhang, and A.J. Zhang Emodin and baicalein inhibit pancreatic stromal derived factor-1 expression in rats with acute pancreatitis Hepatobiliary and Pancreatic Diseases International 8 2009 201 208
45. K.G. Lim, A.I. Gray, S. Pyne, and N.J. Pyne Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival British Journal of Pharmacology 166 2012 1605 1616
46. H. Liu, M. Sugiura, V.E. Nava, L.C. Edsall, K. Kono, S. Poulton, S. Milstien, T. Kohama, and S. Spiegel Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform Journal of Biological Chemistry 275 2000 19513 19520 (Pubitemid 30441543)
47. H. Liu, R.E. Toman, S.K. Goparaju, M. Maceyka, V.E. Nava, H. Sankala, S.G. Payne, M. Bektas, I. Ishii, J. Chun, S. Milstien, and S. Spiegel Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis Journal of Biological Chemistry 278 2003 40330 40336 (Pubitemid 37248601)
48. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent Journal of Biological Chemistry 193 1951 265 275
49. M. Maceyka, H. Sankala, N.C. Hait, H. Le Stunff, H. Liu, R. Toman, C. Collier, M. Zhang, L.S. Satin, A.H. Merrill, S. Milstien, and S. Spiegel SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism Journal of Biological Chemistry 280 2005 37118 37129 (Pubitemid 41587796)
50. A.C. MacKinnon, A. Buckley, E.R. Chilvers, A.G. Rossi, C. Haslett, and T. Sethi Sphingosine kinase: a point of convergence in the action of diverse neutrophil priming agents Journal of Immunology 169 2002 6394 6400 (Pubitemid 36903488)
51. F. Maestrelli, M. Cirri, G. Corti, N. Mennini, and P. Mura Development of enteric-coated calcium pectinate microspheres intended for colonic drug delivery European Journal of Pharmaceutics and Biopharmaceutics 69 2008 508 518
52. L.W. Maines, L.R. Fitzpatrick, K.J. French, Y. Zhuang, Z. Xia, S.N. Keller, J.J. Upson, and C.D. Smith Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase Digestive Diseases and Sciences 53 2008 997 1012
53. L.W. Maines, L.R. Fitzpatrick, C.L. Green, Y. Zhuang, and C.D. Smith Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease Inflammopharmacology 18 2010 73 85
54. A.R. Martín, I. Villegas, C. La Casa, and C.A. de la Lastra Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats Biochemical Pharmacology 67 2004 1399 1410 (Pubitemid 38315105)
55. A.R. Martín, I. Villegas, M. Sánchez-Hidalgo, and C.A. de la Lastra The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model British Journal of Pharmacology 147 2006 873 885
56. D. May, S. Pan, D.A. Crispin, K. Lai, M.P. Bronner, J. Hogan, D.M. Hockenbery, M. McIntosh, T.A. Brentnall, and R. Chen Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics Journal of Proteome Research 10 2011 200 209
57. J. Meier, and A. Sturm Current treatment of ulcerative colitis World Journal of Gastroenterology 17 2011 3204 3212
58. M. Nagahori, Y. Nemoto, and M. Watanabe Pathogenesis of inflammatory bowel diseases Intestinal Research 8 2010 9 17
59. T. Olsen, R. Goll, G. Cui, A. Husebekk, B. Vonen, G.S. Birketvedt, and J. Florholmen Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis Scandinavian Journal of Gastroenterology 42 2007 1312 1320 (Pubitemid 47537070)
60. K.R. Patel, V.A. Brown, D.J. Jones, R.G. Britton, D. Hemingway, A.S. Miller, K.P. West, T.D. Booth, M. Perloff, J.A. Crowell, D.E. Brenner, W.P. Steward, A.J. Gescher, and K. Brown Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients Cancer Research 70 2010 7392 7399
61. A.B. Pithadia, and S. Jain Treatment of inflammatory bowel disease (IBD) Pharmacological Reports 63 2011 629 642
62. S.M. Pitson, P.A. Moretti, J.R. Zebol, R. Zareie, C.K. Derian, A.L. Darrow, J. Qi, R.J. D'Andrea, C.J. Bagley, M.A. Vadas, and B.W. Wattenberg The nucleotide-binding site of human sphingosine kinase 1 Journal of Biological Chemistry 277 2002 49545 49553 (Pubitemid 36014393)
63. C. Pohl, A. Hombach, and W. Kruis Chronic inflammatory bowel disease and cancer Hepatogastroenterology 47 2000 57 70 (Pubitemid 30085390)
64. E.E. Prieschl, R. Csonga, V. Novotny, G.E. Kikuchi, and T. Baumruker The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after Fc epsilon receptor I triggering Journal of Experimental Medicine 190 1999 1 8 (Pubitemid 29330118)
65. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited FASEB Journal 22 2008 659 661 (Pubitemid 351348146)
66. S. Sánchez-Fidalgo, A. Cárdeno, I. Villegas, E. Talero, and C.A. de la Lastra Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice European Journal of Pharmacology 633 2010 78 84
67. Y. Schneider, B. Duranton, F. Gossé, R. Schleiffer, N. Seiler, and F. Raul Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis Nutrition and Cancer 39 2001 102 107 (Pubitemid 32880955)
68. J.B. Seidelin, and O.H. Nielsen Epithelial apoptosis: cause or consequence of ulcerative colitis? Scandinavian Journal of Gastroenterology 44 2009 1429 1434
69. D.Q. Shih, and S.R. Targan Insights into IBD Pathogenesis Current Gastroenterology Reports 11 2009 473 480
70. Y. Shukla, and R. Singh Resveratrol and cellular mechanisms of cancer prevention Annals of the New York Academy of Sciences 1215 2011 1 8
71. M.V. Singer, H. Schmausser, and G. Schönfeld Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis - results of a field study Hepatogastroenterology 53 2006 317 321 (Pubitemid 43954398)
72. U.P. Singh, S. Singh, D.D. Taub, and J.W. Lillard Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice Journal of Immunology 171 2003 1401 1406 (Pubitemid 36900073)
73. J. Sipos The pathogenesis of ulcerative colitis-associated colorectal cancer Magyar Onkilógia 48 2004 35 43
74. A.J. Snider, T. Kawamori, S.G. Bradshaw, K.A. Orr, G.S. Gilkeson, Y.A. Hannun, and L.M. Obeid A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis FASEB Journal 23 2009 143 152
75. A.J. Snider, K.A. Orr Gandy, and L.M. Obeid Sphingosine kinase: role in regulation of bioactive sphingolipid mediators in inflammation Biochimie 92 2010 707 715
76. G.M. Strub, M. Maceyka, N.C. Hait, S. Milstien, and S. Spiegel Extracellular and intracellular actions of sphingosine-1-phosphate Advances in Experimental Medicine and Biology 688 2010 141 155
77. L. Tessitore, A. Davit, I. Sarotto, and G. Caderni Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression Carcinogenesis 21 2000 1619 1622 (Pubitemid 30608219)
78. J.K. Triantafillidis, G. Nasioulas, and P.A. Kosmidis Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies Anticancer Research 29 2009 2727 2737
79. C.J. van der Woude, H. Moshage, M. Homan, J.H. Kleibeuker, P.L. Jansen, and H. van Dekken Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis Journal of Clinical Pathology 58 2005 811 814 (Pubitemid 41113386)
80. O. Vang, N. Ahmad, C.A. Baile, J.A. Baur, K. Brown, A. Csiszar, D.K. Das, D. Delmas, C. Gottfried, H.Y. Lin, Q.Y. Ma, P. Mukhopadhyay, N. Nalini, J.M. Pezzuto, T. Richard, Y. Shukla, Y.J. Surh, T. Szekeres, T. Szkudelski, T. Walle, and J.M. Wu What is new for an old molecule? Systematic review and recommendations on the use of resveratrol PLoS One 6 2011 e19881
81. A.C. von Roon, G. Reese, J. Teare, V. Constantinides, A.W. Darzi, and P.P. Tekkis The risk of cancer in patients with Crohn's disease Diseases of the Colon and Rectum 50 2007 839 855 (Pubitemid 46870441)
82. L.D. Williams, G.A. Burdock, J.A. Edwards, M. Beck, and J. Bausch Safety studies conducted on high-purity trans-resveratrol in experimental animals Food and Chemical Toxicology 47 2009 2170 2182
83. R.H. Wong, P.R. Howe, J.D. Buckley, A.M. Coates, I. Kunz, and N.M. Berry Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure Nutrition, Metabolism and Cardiovascular Diseases 21 2011 851 856
84. P. Xia, J.R. Gamble, K.A. Rye, L. Wang, C.S. Hii, P. Cockerill, Y. Khew-Goodall, A.G. Bert, P.J. Barter, and M.A. Vadas Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway Proceedings of the National Academy of Sciences of the United States of America 95 1998 14196 14201 (Pubitemid 28549344)
85. J. Yao, J.Y. Wang, L. Liu, Y.X. Li, A.Y. Xun, W.S. Zeng, C.H. Jia, X.X. Wei, J.L. Feng, L. Zhao, and L.S. Wang Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis Archives of Medical Research 41 2010 288 294